HAOHAI BIOTEC (06826) announced that to improve the efficiency of raised funds and make reasonable use of temporarily idle capital, the company plans to utilize up to RMB 300 million (inclusive) of idle raised funds for cash management. This initiative aims to enhance company returns and deliver greater value to shareholders, without affecting ongoing fund projects, compromising fund safety, or altering the intended use of the funds.

The approved funds will be available for cash management within 12 months from the board's approval date, with flexibility for rolling utilization within the specified limit and period.